Professor Zhang Xiaotian: Gastric Cancer and Supportive Oncology Expert in Beijing

Professor Zhang Xiaotian: Gastric Cancer and Supportive Oncology Expert in Beijing

Professor Zhang Xiaotian: Gastric Cancer and Whole-Course Oncology Care

Professor Zhang Xiaotian is a medical oncologist, professor, and doctoral supervisor at Peking University Cancer Hospital. Her clinical work focuses on gastric cancer, gastroesophageal junction cancer, systemic treatment, nutrition, symptom control, and coordinated care throughout the cancer journey.

For an overview of the hospital, see our Peking University Cancer Hospital international patient guide. Patients researching surgery can read our profile of Professor Ji Jiafu, while those exploring precision systemic treatment can review Professor Shen Lin.

Clinical Specialties

  • gastric and gastroesophageal junction cancer;
  • perioperative chemotherapy;
  • advanced and recurrent gastrointestinal cancer;
  • targeted therapy and immunotherapy;
  • cancer-related malnutrition and weight loss;
  • symptom and toxicity management;
  • supportive and palliative oncology; and
  • multidisciplinary treatment planning.

Gastric Cancer Treatment

Treatment depends on stage, tumor location, pathology, biomarkers, nutritional condition, organ function, and previous therapy. Early tumors may be suitable for endoscopic treatment or surgery, while locally advanced disease often requires systemic treatment before or after surgery.

Metastatic disease is usually treated with chemotherapy, targeted therapy, immunotherapy, antibody-drug conjugates, clinical trials, or an individualized combination. Treatment should balance tumor control with symptoms, nutrition, function, and quality of life.

Gastroesophageal Junction Cancer

Tumors where the esophagus meets the stomach can require input from medical oncology, surgery, radiation oncology, pathology, radiology, gastroenterology, and nutrition. Precise classification matters because treatment strategies can differ according to the tumor’s center and extent.

Biomarker-Guided Therapy

Advanced gastric cancer may be tested for HER2, mismatch repair or microsatellite instability, PD-L1, CLDN18.2, and selected genomic alterations. These results can influence targeted and immune treatment choices.

A positive biomarker does not guarantee benefit. Test method, tissue quality, treatment setting, prior therapy, and medicine availability all matter.

Nutrition and Weight Loss

Gastric and esophageal cancers can cause early fullness, difficulty swallowing, nausea, bleeding, poor appetite, and severe weight or muscle loss. Treatment can further affect intake and absorption.

Nutrition support should begin early and may involve diet modification, oral supplements, symptom treatment, tube feeding, or intravenous nutrition in selected circumstances. The goal is not only weight gain, but also preserving strength and the ability to complete treatment.

Managing Treatment Side Effects

Common problems include nausea, diarrhea, constipation, mouth sores, neuropathy, fatigue, low blood counts, infection, skin reactions, and immune-related inflammation. Early reporting often allows safer treatment adjustment and better symptom control.

Fever during chemotherapy, uncontrolled vomiting, severe dehydration, bleeding, new breathing difficulty, confusion, or intense pain requires urgent local assessment.

Supportive and Palliative Oncology

Supportive care can be provided alongside active cancer treatment. It addresses pain, nutrition, sleep, mood, family communication, treatment decisions, and practical problems. It is not limited to end-of-life care.

A whole-course approach helps align treatment intensity with the patient’s goals and can reduce avoidable interruptions or hospital admissions.

Who May Consider a Consultation?

  • patients with newly diagnosed gastric or gastroesophageal junction cancer;
  • patients needing a second opinion on treatment before or after surgery;
  • patients with recurrent or metastatic disease;
  • patients with significant weight loss or difficulty eating;
  • patients experiencing serious treatment toxicity;
  • patients whose cancer progressed after standard therapy;
  • patients needing biomarker or pathology review; or
  • patients seeking a coordinated treatment and supportive-care plan.

Medical Records to Prepare

  • a concise medical summary and exact treatment timeline;
  • endoscopy reports and images;
  • CT, MRI, and PET-CT in original DICOM format;
  • pathology reports, slides, and paraffin blocks;
  • HER2, PD-L1, mismatch repair, CLDN18.2, and sequencing reports;
  • operative and radiotherapy records;
  • every systemic treatment with response and toxicity;
  • recent blood tests, weight trend, and nutrition assessment;
  • a complete medication list; and
  • a clear list of treatment priorities and questions.

How CMCS Can Assist

CMCS – China Medical Concierge Shanghai is an independent medical concierge and health management company, not a hospital. We assist international patients with organizing and translating oncology records, identifying an appropriate specialist, requesting appointment availability, arranging interpretation, and planning medical travel in China.

Remote review requires physician authorization. Access to Professor Zhang, treatment, or clinical trials is subject to hospital approval, and CMCS does not guarantee appointments, eligibility, or outcomes.

Important Note

Doctor roles, biomarker requirements, medicine approvals, trial availability, and appointment arrangements may change. This profile is for general information only and does not replace assessment by a qualified oncology team.

0 تعليق

إرسال تعليق